149 related articles for article (PubMed ID: 26935787)
1. Characteristics of Pediatric Exposures to Antidementia Drugs Reported to a Poison Control System.
Thornton SL; Pchelnikova JL; Cantrell FL
J Pediatr; 2016 May; 172():147-50. PubMed ID: 26935787
[TBL] [Abstract][Full Text] [Related]
2. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Lavikainen P; Hartikainen S; Taipale H
Ann Med; 2017 May; 49(3):230-239. PubMed ID: 27786552
[TBL] [Abstract][Full Text] [Related]
3. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
Inglis F
Int J Clin Pract Suppl; 2002 Jun; (127):45-63. PubMed ID: 12139367
[TBL] [Abstract][Full Text] [Related]
4. Antidementia drug treatment in people screened positive for dementia in primary care.
Wucherer D; Eichler T; Kilimann I; Hertel J; Michalowsky B; Thyrian JR; Teipel S; Hoffmann W
J Alzheimers Dis; 2015; 44(3):1015-21. PubMed ID: 25391382
[TBL] [Abstract][Full Text] [Related]
5. Review of Experience of a Statewide Poison Control Center With Pediatric Exposures to Oral Antineoplastic Drugs in the Nonmedical Setting.
Thornton SL; Liu J; Soleymani K; Romasco RL; Farid H; Clark RF; Cantrell FL
Am J Ther; 2016; 23(2):e377-81. PubMed ID: 23884076
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of centrally acting cholinesterase inhibitor exposures in adults.
McCain KR; Sawyer TS; Spiller HA
Ann Pharmacother; 2007 Oct; 41(10):1632-7. PubMed ID: 17848422
[TBL] [Abstract][Full Text] [Related]
7. Adverse Drug Event Profile Associated with Anti-dementia Drugs: Analysis of a Spontaneous Reporting Database.
Kose E; Yamamoto T; Tate N; Ando A; Enomoto H; Yasuno N
Pharmazie; 2023 May; 78(5):42-46. PubMed ID: 37189266
[TBL] [Abstract][Full Text] [Related]
8. Risk of pneumonia in new users of cholinesterase inhibitors for dementia.
Lai EC; Wong MB; Iwata I; Zhang Y; Hsieh CY; Kao Yang YH; Setoguchi S
J Am Geriatr Soc; 2015 May; 63(5):869-76. PubMed ID: 25912671
[TBL] [Abstract][Full Text] [Related]
9. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
Cumbo E; Ligori LD
J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
[TBL] [Abstract][Full Text] [Related]
10. Castor bean seed ingestions: a state-wide poison control system's experience.
Thornton SL; Darracq M; Lo J; Cantrell FL
Clin Toxicol (Phila); 2014 Apr; 52(4):265-8. PubMed ID: 24579983
[TBL] [Abstract][Full Text] [Related]
11. Antidementia drug treatment in dementia networks in Germany: use rates and factors associated with treatment use.
Wübbeler M; Wucherer D; Hertel J; Michalowsky B; Heinrich S; Meyer S; Schaefer-Walkmann S; Hoffmann W; Thyrian JR
BMC Health Serv Res; 2015 May; 15():205. PubMed ID: 25998147
[TBL] [Abstract][Full Text] [Related]
12. Characteristic effects of anti-dementia drugs on rat sleep patterns.
Ishida T; Kamei C
J Pharmacol Sci; 2009 Mar; 109(3):449-55. PubMed ID: 19305123
[TBL] [Abstract][Full Text] [Related]
13. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
[TBL] [Abstract][Full Text] [Related]
14. Unintentional pediatric exposures to central alpha-2 agonists reported to the National Poison Data System.
Wang GS; Le Lait MC; Heard K
J Pediatr; 2014 Jan; 164(1):149-52. PubMed ID: 24094880
[TBL] [Abstract][Full Text] [Related]
15. [Drugs used for cognitive impairment. Analysis of 1.5 million prescriptions in Argentina].
Rojas G; Demey I; Arizaga RL
Medicina (B Aires); 2013; 73(3):213-23. PubMed ID: 23732196
[TBL] [Abstract][Full Text] [Related]
16. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
Prescrire Int; 2006 Jun; 15(83):103-6. PubMed ID: 16764099
[TBL] [Abstract][Full Text] [Related]
17. Drugs for cognitive loss and dementia.
Treat Guidel Med Lett; 2013 Oct; 11(134):95-100; quiz 1 p following p100.. PubMed ID: 24081314
[TBL] [Abstract][Full Text] [Related]
18. Human bromethalin exposures reported to a U.S. Statewide Poison Control System.
Huntington S; Fenik Y; Vohra R; Geller RJ
Clin Toxicol (Phila); 2016 Mar; 54(3):277-81. PubMed ID: 26860212
[TBL] [Abstract][Full Text] [Related]
19. Cholinesterase inhibitors and incidence of bradycardia in patients with dementia in the veterans affairs new England healthcare system.
Hernandez RK; Farwell W; Cantor MD; Lawler EV
J Am Geriatr Soc; 2009 Nov; 57(11):1997-2003. PubMed ID: 19793162
[TBL] [Abstract][Full Text] [Related]
20. Deterioration in donepezil-induced PR prolongation after a coadministration of memantine in a patient with Alzheimer's disease.
Igeta H; Suzuki Y; Motegi T; Sasaki A; Yokoyama Y; Someya T
Gen Hosp Psychiatry; 2013; 35(6):680.e9-10. PubMed ID: 23731891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
